Drugs / [ Lu-177]-Catalase
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05985278 | Jul 2023 → Jun 2026 | cancer | Peking University Cancer Hospital & Institute | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [ Lu-177]-Catalase | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05985278 ↗ |
| Route | Other | “\[ 177Lu\]-Catalase is administered by intratumoral puncture every four weeks” NCT05985278 ↗ |